Table 2 Effect of rituximab treatment in patients with rheumatoid arthritis
From: Suppressed diversity of survivin splicing in active rheumatoid arthritis
Before RTX | After RTXa | |
|---|---|---|
DAS28 score | 5.89 ± 0.6 | 4.34 ± 0.7 |
Rheumatoid factor (IU/ml) | ||
IgG | 41.5 ± 29.3 | 22.7 ± 19.5* |
IgM | 67.2 ± 31.1 | 50.2 ± 38.3 |
IgA | 41.0 ± 38.3 | 25.0 ± 19.5 |
WBC count (×109/l) | ||
PBMCs | 6.5 ± 3.1 | 7.8 ± 3.2 |
BM | 2.1 ± 1.4 | 2.6 ± 1.6 |
CD19+ (%)b | ||
PBMCs | 7.7 ± 3.8 | 0 |
BM | 9.4 ± 4.3 | 1.3 ± 1.2† |
CD3+ (%)b | ||
PBMCs | 45.9 ± 15.8 | 42.5 ± 12.9 |
BM | 28.0 ± 9.8 | 29.4 ± 16.5 |